

BLAU FARMACÊUTICA S.A.

Publicly Held Company

NIRE 35.300.416.406

CVM Code No. 2462-7

MATERIAL FACT**Exceptional Treatment with Respect to Compliance with the Minimum Percentage of Outstanding Shares**

BLAU FARMACÊUTICA S.A. (Ticker: **BLAU3**; "Blau" or "Company"), in compliance with the provisions of CVM Resolution No. 44, of August 23, 2021, as amended, and in addition to the Material Facts disclosed on April 14, 2021, June 6, 2022, September 22, 2023, October 10, 2023, December 13, 2024, and June 4, 2025, hereby informs its shareholders and the market in general that, considering the deadline for the Company's compliance with the minimum percentage of shares outstanding in the market (free float) and the macroeconomic scenario, B3's Executive Board approved the automatic extension of the deadline for the Company to comply with the free float requirement from December 31, 2026, to December 31, 2027.

Cotia, September 9, 2026

Douglas Leandro Rodrigues
Chief Financial and Investor Relations Officer

About Blau Farmacêutica:

Blau is a leading multinational pharmaceutical company in the hospital segment and a pioneer in biotechnology in Brazil, with a portfolio of proprietary brands of highly complex medicines focused on relevant segments in the industry, such as immunology, hematology, oncology, nephrology, infectious diseases, and several other therapeutic classes. Blau has an international presence, operating in Brazil and seven other Latin American countries (Argentina, Colombia, Chile, Ecuador, Mexico, Peru, and Uruguay), in addition to a plasma collection operation in the United States. It has a modern pharmaceutical industrial complex in Brazil, consisting of five industrial plants with state-of-the-art technology, dedicated to serving the local market and exports.